公开(公告)号：US20210009949A1

公开(公告)日：2021-01-14

申请号：US16900432

申请日：2020-06-12

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Marine Prissette ,  Matthew Koss ,  Mathieu Desclaux ,  John McWhirter ,  Arijit Bhowmick ,  David Frendewey ,  Brian Zambrowicz

IPC: C12N5/0793 ,  A61K9/00 ,  A61K48/00 ,  C12N15/113

Abstract: BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.

公开(公告)号：US12209238B2

公开(公告)日：2025-01-28

申请号：US18502499

申请日：2023-11-06

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Marine Prissette ,  Matthew Koss ,  Wen Fury ,  Brian Zambrowicz

IPC: C12N15/10 ,  A61K48/00 ,  C12N5/00 ,  C12N5/071 ,  C12N9/22 ,  C12N15/113 ,  G01N21/64 ,  G01N33/68 ,  G16B25/00

Abstract: Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.

公开(公告)号：US20240409891A1

公开(公告)日：2024-12-12

申请号：US18819435

申请日：2024-08-29

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Marine Prissette ,  Matthew Koss ,  Mathieu Desclaux ,  John McWhirter ,  Arijit Bhowmick ,  David Frendewey ,  Brian Zambrowicz ,  Claudia Racioppi

IPC: C12N5/0793 ,  A61K9/00 ,  A61K48/00 ,  C12N15/113

Abstract: BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.

公开(公告)号：US20240076613A1

公开(公告)日：2024-03-07

申请号：US18502516

申请日：2023-11-06

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Marine Prissette ,  Matthew Koss ,  Mathieu Desclaux ,  John McWhirter ,  Arijit Bhowmick ,  David Frendewey ,  Brian Zambrowicz ,  Claudia Racioppi

IPC: C12N5/0793 ,  A61K9/00 ,  A61K48/00 ,  C12N15/113

CPC classification number: C12N5/0619 ,  A61K9/0019 ,  A61K48/0058 ,  C12N15/113 ,  C12N2310/11

Abstract: BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.

公开(公告)号：US20220167600A1

公开(公告)日：2022-06-02

申请号：US17553115

申请日：2021-12-16

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Vera Voronina ,  Lynn Macdonald ,  Marine Prissette ,  Ka-Man Venus Lai ,  Ashok Badithe ,  Andrew J. Murphy ,  Gustavo Droguett ,  David Frendewey ,  Brian Zambrowicz

IPC: A01K67/027 ,  C07K16/00 ,  C12N15/90 ,  C12N9/64 ,  C12N15/85

Abstract: Methods and compositions are provided for generating antigen-binding proteins against a foreign antigen of interest.

公开(公告)号：US20170332610A1

公开(公告)日：2017-11-23

申请号：US15600466

申请日：2017-05-19

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Vera Voronina ,  Lynn Macdonald ,  Marine Prissette ,  Ka-Man Venus Lai ,  Ashok Badithe ,  Andrew J. Murphy ,  Gustavo Droguett ,  David Frendewey ,  Brian Zambrowicz

IPC: A01K67/027 ,  C12N15/85 ,  C12N9/64

CPC classification number: A01K67/0278 ,  A01K67/0271 ,  A01K67/0276 ,  A01K2207/05 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/02 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C12N9/6489 ,  C12N15/8509 ,  C12N15/90 ,  C12N2015/8518 ,  C12Y301/00 ,  C12Y304/24046

Abstract: Methods and compositions are provided for making non-human animals with reduced tolerance of a foreign antigen of interest and making antigen-binding proteins against that foreign antigen of interest using such animals. The methods and compositions employ CRISPR/Cas9 systems using multiple guide RNAs to reduce or eliminate expression of a self-antigen homologous to or sharing an epitope of interest with the foreign antigen of interest or to reduce or eliminate expression of an epitope on the self-antigen that is shared with the foreign antigen of interest.

公开(公告)号：US12110502B2

公开(公告)日：2024-10-08

申请号：US18502516

申请日：2023-11-06

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Marine Prissette ,  Matthew Koss ,  Mathieu Desclaux ,  John McWhirter ,  Arijit Bhowmick ,  David Frendewey ,  Brian Zambrowicz ,  Claudia Racioppi

IPC: C12N15/113 ,  A61K9/00 ,  A61K48/00 ,  C12N5/0793 ,  C12Q1/68 ,  C07H21/02

CPC classification number: C12N5/0619 ,  A61K9/0019 ,  A61K48/0058 ,  C12N15/113 ,  A01K2267/0312 ,  A01K2267/0318 ,  C12N2310/11

Abstract: BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.

公开(公告)号：US11845957B2

公开(公告)日：2023-12-19

申请号：US16900432

申请日：2020-06-12

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Marine Prissette ,  Matthew Koss ,  Mathieu Desclaux ,  John McWhirter ,  Arijit Bhowmick ,  David Frendewey ,  Brian Zambrowicz ,  Claudia Racioppi

IPC: C12N5/0793 ,  C12N15/113 ,  A61K9/00 ,  A61K48/00 ,  C12Q1/68

CPC classification number: C12N5/0619 ,  A61K9/0019 ,  A61K48/0058 ,  C12N15/113 ,  C12N2310/11

Abstract: BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.

公开(公告)号：US20200299682A1

公开(公告)日：2020-09-24

申请号：US16821453

申请日：2020-03-17

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Marine Prissette ,  Matthew Koss ,  Wen Fury ,  Brian Zambrowicz

IPC: C12N15/10 ,  C12N15/113 ,  C12N9/22 ,  C12N5/073 ,  C12N5/071

Abstract: Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.

公开(公告)号：US20200299681A1

公开(公告)日：2020-09-24

申请号：US16821384

申请日：2020-03-17

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Marine Prissette ,  Matthew Koss ,  Yu Bai ,  Brian Zambrowicz

IPC: C12N15/10 ,  C12N15/113 ,  C12N9/22

Abstract: Cas-protein-ready tau bio sensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic vulnerability associated with tau aggregation are provided.